Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Developing drugs for the rare, aggressive glioblastoma, the most common and malignant type of glioma, or brain cancer, was never easy. But a brain cancer drug’s journey through Phase III and to the finish line of market entry today is more arduous than ever.

You may also be interested in...



Start-Up Tries Crowdfunding To Revive Brain Cancer Drug Berubicin

Emerging Company Profile: Texas start-up CNS Pharmaceuticals sees a bright future for blood-brain barrier-crossing berubicin, which is nearing the end of its patent life.

Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?

The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.

Merck Out-Licenses Gene Therapy Assets To FKD Therapies

Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.

Related Content

Topics

UsernamePublicRestriction

Register

PS004565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel